ライフサイエンスコーパス: vascular tumor

1 ead to novel therapeutic treatments for this vascular tumor.

2 should be aware of this low-grade cutaneous vascular tumor.

3 antile hemangioma (IH) is a common childhood vascular tumor.

4 re closed using particles filling the entire vascular tumor.

5 y to show direct evidence of EPCs in a human vascular tumor.

6 a higher incidence of metastasis than poorly vascular tumors.

7 he pathogenesis of both benign and malignant vascular tumors.

8 ene family have been identified in childhood vascular tumors.

9 AZ-CAMTA1 results in the regression of these vascular tumors.

10 diagnosis of congenital hemangioma for these vascular tumors.

11 g treatment strategy because GBMs are highly vascular tumors.

12 ential therapeutic agent in this category of vascular tumors.

13 erefore was not due to the selection of more vascular tumors.

14 rocess may be useful in treating cancers and vascular tumors.

15 gioendotheliomas and perhaps other cutaneous vascular tumors.

16 a mutant FOS protein we identified in these vascular tumors.

17 essing cells were present at the site of the vascular tumors.

18 ype, including those of benign and malignant vascular tumors (0 of 3 hemangiomas, 0 of 1 hemangioendo

19 fistula, and arteriovenous malformation) and vascular tumors allows for timely diagnosis and appropri

20 ment for Kaposi's sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis.

21 s (KSHV) is a highly angiogenic and invasive vascular tumor and the most common AIDS-associated cance

22 ely, animals lacking both genes develop many vascular tumors and also present with medulloblastomas n

23 in as a novel treatment for nonmetastasizing vascular tumors and for Kasabach-Merritt syndrome.

24 y of beta adrenergic inhibition on malignant vascular tumors and have laid the groundwork for a promi

25 rt that the loss of Notch1 caused widespread vascular tumors and organism lethality secondary to mass

26 Hif-1alpha did not affect the development of vascular tumors and polycythemia, nor did it suppress th

27 nt HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-

28 y of Vascular Anomalies into 2 major groups: vascular tumors and vascular malformations.

29 Kaposi's sarcoma is a highly vascular tumor, and recently both hypoxia-inducible fact

30 genic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG1 abrogated tumori

31 11 can cause certain types of rare childhood vascular tumors, and we have now identified causal recur

32 Vascular tumors are among the most common neoplasms in i

33 Vascular tumors are endothelial cell neoplasms whose mec

34 Vascular tumors are not a known complication of antiangi

35 -twin transfusion syndrome, lung masses, and vascular tumors, are highlighted.

36 ubtype transition in glioma cells located in vascular tumor areas, highlighting its role in glioblast

37 Vascular tumors arising after intradermal injection of i

38 Kaposi's sarcoma (KS) is a rare vascular tumor associated with human herpesvirus (HHV)-8

39 Kaposi's sarcoma (KS), a vascular tumor associated with human immunodeficiency vi

40 n the therapeutic algorithm for IH and other vascular tumors awaits controlled study.

41 The angiograms showed an intense vascular tumor blush in recurrent mass lesions supplied

42 Purpose To quantify initial changes in the vascular tumor burden (VTB), a measure of the area of va

43 changes ranging from erythematous maculae to vascular tumors, by the presence of spindle and inflamma

44 c mimicry (VM) is the phenomenon whereby non-vascular tumor cells develop vascular-like structures.

45 Beta blockade is selective for vascular tumor cells over normal endothelial cells and s

46 Conversely, S6K signaling was increased in vascular tumor cells where Akt3 was silenced, and the gr

47 Kaposi's sarcoma is a vascular tumor commonly associated with human immunodefi

48 blocking autocrine VEGF signaling abolished vascular tumor development and growth.

49 Animal models for this class of vascular tumors do not exist.

50 Vascular tumors encompass proliferative lesions ranging

51 that local application of imiquimod inhibits vascular tumor enlargement in the mouse vascular tumor m

52 r soft part sarcoma (ASPS) is a rare, highly vascular tumor, for which no effective standard systemic

53 etiologic agent of Kaposi's sarcoma (KS), a vascular tumor frequently found in immunodeficient indiv

54 del describes the spatiotemporal dynamics of vascular tumor growth and treats cells as distinct entit

55 ilding upon previous work, here we develop a vascular tumor growth model by coupling a continuous gro

56 We apply our recently developed vascular tumor growth model which couples a continuous g

57 ro cell proliferation model and a complex 3D vascular tumor growth model.

58 potential for PDT-BPD to inhibit selectively vascular tumor growth was tested in a mouse angiosarcoma

59 a, (2) mechanistic modeling of avascular and vascular tumor growth, and (3) modeling of cancer initia

60 ation, where Akt1 promotes and Akt3 inhibits vascular tumor growth.

61 transgenic animals expressing vGPCR manifest vascular tumors histologically identical to human KS, wi

62 with the adjacent myocardium, malignant and vascular tumors hyper-enhanced, whereas stromal tumors a

63 wledge, angiomyolipomas are the first benign vascular tumor in which the vascular cells, rather than

64 ative lesions from vascular malformations to vascular tumors in adult mice.

65 n tumors, male hepatocellular tumors, and in vascular tumors in both sexes.

66 ation of endothelial cell-derived intramural vascular tumors in the implantation site.

67 ence that chronic Notch1 inhibition leads to vascular tumors in the liver and decreased survival, whi

68 cally that the development of VHL-associated vascular tumors in the liver depends on functional ARNT.

69 omas (PGs) are commonly encountered, benign, vascular tumors, in which epidemiologic factors have bee

70 t typically regress by 5 years of age; other vascular tumors include congenital tufted angiomas (TAs)

71 It is characterized clinically by vascular tumors including benign hemangioblastomas of th

72 e characterized by the development of highly vascular tumors including hemangioblastomas of the retin

73 es in the global gene expression patterns of vascular tumors, including alterations in the expression

74 Lindau disease (VHL) patients develop highly vascular tumors, including central nervous system hemang

75 red in a series of central cartilaginous and vascular tumors, including samples from syndromic and no

76 M recurrence and highlight the importance of vascular-tumor interactions for GBM development.

77 choroidal hemangioma is an uncommon, benign vascular tumor manifesting as an orange-red mass in the

78 were indeed present and therefore aggressive vascular tumors may similarly show increased susceptibil

79 bits vascular tumor enlargement in the mouse vascular tumor model suggests a novel, less toxic means

80 Vascular tumors occur in approximately 10% of all infant

81 represent a heterogeneous group of malignant vascular tumors occurring not only in different anatomic

82 angiofibromas (JNAs) are locally aggressive vascular tumors occurring predominantly in adolescent ma

83 ogically associated with Kaposi's sarcoma, a vascular tumor of endothelial cells.

84 fantile hemangioma is the most common benign vascular tumor of infancy.

85 Kaposi's sarcoma (KS) is a vascular tumor of proliferative endothelial cells caused

86 ndle cell hemangioma (SCH) is a rare, benign vascular tumor of the dermis and subcutis.

87 he pathogenesis, diagnosis and management of vascular tumors of infancy in the past year.

88 ds to VHL disease, which is characterized by vascular tumors of the central nervous system, renal cle

89 sia syndromes and is characterized by highly vascular tumors of the eyes, brain, and spine, as well a

90 tify GNA14 mutations as a cause of childhood vascular tumors, offer insight into mechanisms of oncoge

91 A vascular anomaly could be a vascular tumor or a vascular malformation.

92 rus 8 (KSHV/ HHV8), has not been reported in vascular tumors other than KS.

93 to the nanodrug to inhibit the expression of vascular tumor protein laminin-411 in order to block tum

94 Vascular tumors ranged in severity from angiomas to hema

95 ent 129/J mice with life-threatening primary vascular tumors reduced tumor volume 7.5-fold and almost

96 Kaposi sarcoma is a vascular tumor related to herpesvirus-8 and is promoted

97 Histology disclosed intramural vascular tumors resembling hemangiomas in the VEGF-myobl

98 ession of only KDR observed in the malignant vascular tumors studied.

99 ession of these receptors on more aggressive vascular tumors such as hemangioendotheliomas and angios

100 markable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas.

101 cept for the therapeutic utility of treating vascular tumors, such as angiosarcomas, with S6K inhibit

102 Available therapies for vascular tumors, such as systemic corticosteroids, vincr

103 -CAMTA1 in driving the formation of EHE-like vascular tumors, suggesting that constitutive activation

104 ies have not fully realized their promise in vascular tumors, suggesting that these tumors do not dep

105 Congenital hemangioma is a rare vascular tumor that forms in utero.

106 In addition, GCT is a vascular tumor that may occasionally rupture and result

107 Infantile hemangioma (IH) is a benign vascular tumor that occurs in 5% of newborns.

108 sia (PEH) or Masson's tumor is a rare benign vascular tumor that usually appears in the soft tissues

109 liomas are categorized as intermediate-grade vascular tumors that are commonly localized in the lungs

110 Congenital hemangiomas (CHs) are rare benign vascular tumors that differ from common infantile hemang

111 gnant gliomas are locally aggressive, highly vascular tumors that have a dismal prognosis, and presen

112 Renal angiomyolipomas are highly vascular tumors that occur sporadically, in women with p

113 Congenital hemangiomas are uncommon benign vascular tumors that present fully formed at birth.

114 Kaposi's sarcoma (KS) is an enigmatic vascular tumor thought to be a consequence of dysregulat

115 To preserve the delicate vascular tumor tissue structure, and potential classific

116 ry efficiently formed highly invasive and/or vascular tumors upon intracerebral implantation into imm

117 information were gathered, and sections from vascular tumors were stained with vascular endothelial g

118 Hepatocellular cancer is a highly vascular tumor, where the neovasculature is unique in th

119 elioid hemangioendothelioma (HEHE) is a rare vascular tumor which has an intermediate aggressive beha

120 These are highly vascular tumors which overproduce angiogenic peptides su

121 Kaposi's sarcoma is a highly vascular tumor, which preferentially develops in the low

122 elioid hemangioendothelioma (HEHE) is a rare vascular tumor with a high mortality rate.

123 Infantile hemangioma is a common vascular tumor with a unique lifecycle: rapid growth in

124 Hepatocellular carcinoma (HCC) is a vascular tumor with poor prognosis.

125 ells is sufficient to drive the formation of vascular tumors with the distinctive features of EHE, an